Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sitagliptin in Newly Diagnosed Type 2 Diabetes
NCT04495881Phase 4Unknown
- Sponsor
- Beijing Chaoyang Hospital
- Start
- Jan 2020
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of sitagliptin in type 2 diabetes mellitus (T2DM), sponsored by Beijing Chaoyang Hospital. Primary endpoint: Change in Glycated Hemoglobin (HbA1c) at 3 months. Status: unknown.
02
Drugs
sitagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04495881.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04495881.